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Background: The optimal treatment for patients with brain metastasis from gestational trophoblastic neoplasia
(GTN) has not been established. This study aims to investigate the clinical characteristics and the management of
brain metastasis from GTN in relation to patients’ outcomes.
Methods: We retrospectively investigated 109 GTN patients with brain metastasis treated at Peking Union Medical
College Hospital from January 1990 to December 2013. Patients mainly received multiagent chemotherapy with
florouracil or floxuridine, dactinomycin, etoposide, and vincristine (FAEV) combined with intrathecal methotrexate
with or without surgery.
Results: In the 109 patients, sixty-two (56.1%) patients presented for primary therapy and 47 patients had failed
chemotherapy elsewhere. Eight early demise patients who died before or during first cycle of chemotherapy were
excluded from analysis. The median follow-up time was 47 months (range 9–180 months). The overall 5-year survival
rate (OS) was 71.1%, while the OS rate for patients receiving primary chemotherapy in our hospital was 85.5%, and this
fell to 51.9% in patients with failure multidrug chemotherapy elsewhere. Multivariate analysis demonstrated that
International Federation of Gynecology and Obstetrics (FIGO) scores over 12 (Hazard ratio-HR 1.279, 95% CI
1.061-1.541, P = 0.010), failure of previous multidrug chemotherapy (HR 3.177, 95% CI 1.277-7.908, P = 0.013), and
concurrent renal metastasis (HR 2.654, 95% CI 1.125-6.261, P = 0.026) were the risk factors of overall survival in patients
with brain metastases from GTN.
Conclusions: Patients with brain metastasis from GTN have favorable outcome by multidrug chemotherapy and
adjuvant therapies. Nevertheless, the prognosis is poor if the patients had previous multidrug failure chemotherapy
history, concomitant with renal metastasis, or FIGO score over 12. Initial treatment with FAEV combined with
intrathecal methotrexate chemotherapy can bring bright prospect to patients with brain metastases from GTN.
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Gestational trophoblastic neoplasia (GTN) is used to
refer to a group of uncommon malignant gynecological
tumors arising from trophoblastic cells, including inva-
sive mole, choriocarcinoma, placental site trophoblastic
tumor, and epithelioid trophoblastic tumor [1]. Owing to
their remarkable sensitivity to chemotherapy, the cure
rates are almost 100% in the low-risk group and nearly
90% in the high-risk group with current chemotherapy
regimens [2,3]. But the prognosis of certain patients with
GTN is still poor, including those with far-advanced dis-
ease at presentation, and long interval time from the
antecedent pregnancy [4]. In addition, brain metastasis
was also regarded as a poor prognostic factor in previous
reports [5].
Although brain metastasis from GTN is a rare event
with an incidence of 3% to 21.4% and about only 222
cases documented in the literature [5,6], the survival
rates of patients with brain metastasis are significantly
reduced as low as 35-60% [5,7,8]. However, with the rar-
ity of brain metastasis from GTN, there are still no
guidelines on treatment strategies for these patients yet.
Currently available data are derived from some retro-
spective reviews including few patients [5,7-10]. While
the main treatment strategies of these reports were sys-
temic chemotherapy combined with whole-brain radi-
ation therapy. Given the intellectual impairment by
whole-brain radiation therapy over long term in patients,
the study of new effective strategies with limited toxic
effects have become an intense focus of clinical
physicians.
In China, fuorouracil (5-FU) or floxuridine (FUDR)-
based combination chemotherapy (florouracil/floxuri-
dine, dactinomycin, etoposide, and vincristine, FAEV)
was favorable in the management of high-risk GTN in
the Peking Union Medical College Hospital (PUMCH)
for several decades [11-13]. Furthermore, our earlier re-
port demonstrated that FAEV regimen was also an ef-
fective regimen with manageable toxicity for patients
with relapsed/chemoresistant GTN [14]. Therefore,
FAEV combined with intrathecal methotrexate chemo-
therapy is the preferred treatment strategy for the pa-
tients with brain metastasis from GTN in PUMCH. In
the present study, we collected clinical datas of 109
GTN patients with brain metastasis in our hospital from
January 1990 to December 2013, and retrospectively an-
alyzed the management, the prognosis and related risk
factors of patients with brain metastasis in GTN.
Methods
Data collection
From January 1990 to December 2013, there were 3,209
patients with GTN treated at PUMCH. Patients with
brain metastases were identified and reviewed accordingto the International Federation of Gynecology and Ob-
stetrics (FIGO) criteria for GTN [15]. The diagnostic
procedures were computed tomography (CT) or prefera-
bly magnetic resonance imaging (MRI) scan of the brain,
determination of baseline serum human chorionic gona-
dotropin(hCG) level, especially the serum β-hCG level,
and when applicable, cerebrospinal fluid (CSF) hCG:
serum hCG ratio. Approval for this study was obtained
from the PUMCH Research Ethics Committee. And
written informed consents was obtained from the pa-
tients for publication of this retrospective review.
Treatment protocol
On admission, all patients who were highly suspected
with brain metastasis have an initial assessment with de-
tailed history, physical examination, routine blood test,
biochemistry and serum hCG level test, X-ray or CT
scan of chest and B type ultrasound or MRI scan of pel-
vis, and CT or MRI scan of brain. And during the treat-
ment, β-hCG level, routine blood test, and serum
biochemical examination, were monitored weekly for re-
sponse and toxicity.
Patients received a combination of systemic chemother-
apy and intrathecal injection of methotrexate. According
to the previous protocol of chemotherapy, several different
chemotherapy regimens were used. FAEV was used in the
patients who didn’t receive the 5-FU or FUDR-based com-
bination chemotherapy before[13,14]. If drug resistance
had developed or the reduction of the serum β-hCG level
was unsatisfactory [14], a replacement regimen of alternat-
ing etoposide, methotrexate, dactinomycin (EMA) with
cyclophosphamide and vincristine (CO), or alternating
EMA with etoposide and cisplatin (EP) was used. If pa-
tients remained refractory, almost all salvage regimens
were platinum-based. Once the serum β-hCG level was
normal, intrathecal injections were stopped, but patients
still received an additional 2 to 4 courses of consolidation
systemic chemotherapy. The majority of patients required
granulocyte colony-stimulating factor because of blood
toxicity of chemotherapy.
For the patients with chemotherapy-resistant GTN or
with high intracranial pressure which was secondary to
hemorrhage, edema, and tumor volume, adjuvant surgi-
cal procedures including hysterectomy, pulmonary re-
section and craniotomy, were used to remove foci of
chemotherapy resistant disease or reduce intracranial
pressure.
Assessment of curative effect
Complete remission (CR) was defined as normal β-hCG
levels in at least four consecutive weekly determinations.
A partial remission (PR) was defined as serum β-hCG
levels decreased more than 50% or tumor diminished by
more than 50% compared with the pretreatment.
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β-hCG levels continuing plateau/elevated, or appearance
of new metastases for at least two consecutive cycles of
chemotherapy [14].Statistical analysis
Statistical analyses were performed with SPSS 17.0 stat-
istical software (SPSS, Inc., Chicago, IL). Survival was
measured from the date of diagnosis to the date of last
follow-up or death. Cases alive and lost to follow-up at
the end of the follow-up period were considered cen-
sored observations. The overall survival was plotted ac-
cording Kaplan-Meier method, and the univariate log
rank test was used to evaluate the significance of prog-
nostic factors for survival. Multivariate analysis using
Cox proportional regression method was performed for
the covariates selected in univariate analysis. P <0.05
was considered to be statistically significant.Table 1 Clinical characteristics of all GTN Patients with Brain
Characteristic
Age (years), median (range)
Gravidity, median (range)
Parity, median (range)
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FIGO: International Federation of Gynecology and Obstetrics; hCG: human chorionic
FAEV: florouracil/floxuridine, dactinomycin, etoposide, and vincristine,
a Lung metastases excluded;
b Including spinal cord, bladder, adrenal gland, intestinal tract, skin and bone.Results
Patient characteristics
A total of 109 GTN patients were identified as having
brain metastasis at PUMCH in the past 24 years, repre-
senting 3.4% of all patients treated with this cancer at
our hospital during the same period. Among the 109 pa-
tients, 62 patients (56.1%) received primary treatment in
our hospital and the rest 47 patients (43.9%) had failed
multidrug chemotherapy elsewhere.
Table 1 showed detailed patients characteristics. The
median age of the patients was 28 years (range 20–56
years). The most common antecedent pregnancy was
mole in 41 (40.6%), followed by term delivery in 36
(35.6%) and non-molar abortion in 24 (23.8%). 69 pa-
tients (63.3%) had interval time more than one year. The
median pretreatment serum β-hCG levels were
19224mIU/mL (range 62-3049000mIU/mL) before re-
ceiving treatment in our hospital. According to FIGO
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with a median FIGO score of 13 (range 5–23 points).
The distant metastatic sites that were thought to be ar-
tery metastasis included the brain, liver, kidney, and sev-
eral unusual sites such as the bladder, spinal cord,
intestinal tract, adrenal gland, skin and bone. Besides
lung metastasis, 75 patients (68.8%) presented with iso-
lated brain metastases, 25 patients (22.9%) displayed
double-site distant metastases, 6 (5.5%) patients pre-
sented triple-site distant metastases, and 3 patients
(2.8%) displayed more than 3 sites of distant metastases.
Eight early demise patients who died before or during
first cycle of chemotherapy were excluded from the sur-
vival and prognostic factors analysis. All of these patients
had large-volume disease reflected by very high FIGO
scores and multiple metastases (Table 2). What’s more,
apart from one patient with recurrent choriocarcinoma,
almost all of the early-death patients were delayed in the
local hospitals before the definitive diagnosis was made.
Treatment
All patients received multiagent chemotherapy with
FAEV combined with intrathecal methotrexate chemo-
therapy at least two cycles. For the FAEV regimens as
the primary treatment group, 16 patients (28.0%) discon-
tinued FAEV therapy because of no response(13 cases)
or toxic effects(3 cases). While the salvage treatment
group, 24 patients (54.5%) discontinued FAEV therapy
because of drug resistance(17 cases) or toxic effects(7
cases). Of 40 patients with no response or toxic effects,
18 patients achieved CR by further salvage chemother-
apy with or without surgeries.
Of the 109 patients, 68 patients (62.4%) received 85
times of surgical treatment. Among these patients, 15
(13.8%) underwent pelvic operation (hysterectomy or









1 53 15 Abortion 180 99000.0
2 30 21 Abortion 10 906720.0
3 31 8 Mole 32 80.0
4 25 12 Mole 27 57380.0
5 32 12 Term 6 200000.0
6 36 13 Mole 56 9306.0
7 26 15 Term 3 60436.5
8a 33 17 Mole 36 2400.0
AP: antecedent pregnancy; EMA: etoposide, methotrexate, dactinomycin; FAEV: flox
a recurrent choriocarcinoma.surgery (lobotomy or lung lesion resection), 16 (14.7%)
underwent craniotomy, 9 (8.3%) underwent pelvic oper-
ation plus lung surgery, 6 (5.5%) underwent lung surgery
plus craniotomy, and 2 (1.8%) underwent pelvic oper-
ation plus craniotomy. Other surgeries included resec-
tion of unilateral adrenal metastasis (1 case) and partial
resection of the intestine (1 case). Only two patients re-
ceived brain irradiation.
Outcome and survival
Excluding the 8 early-deaths patients, 71 (70.3%) of the
remaining 101 patients achieved CR after the compre-
hensive treatments, 10 (9.9%) patients obtained PR, and
20 (19.8%) patients exhibited PD. Among these 101 pa-
tients there were 26 (25.7%) patients died after initial
treatments. Most patients (22/26) died of intracranial
hemorrhage or with concurrent herniation and multiple
organ failure. In the other 4 patients, 3 died of septic
shock resulting from myelosuppression during treat-
ments, and another one died of respiratory failure. Of
the 57 patients who received primary treatment in our
hospital, 48 (84.2%) patients achieved CR; among the 44
patients who were treated secondarily in our hospital,
only 23 (52.3%) patients achieved CR.
Follow-ups were provided to all survival patients. The
median follow-up time was 47 months (range 8–180
months), but 6 patients lost follow-ups. Among these
patients, 9 (11.3%) patients relapsed within 3 to
84 months after completion of the initial treatment,
most of whom (6/9) relapsed in the first year, and 4 of
them exhibited distant metastasis and died of PD during
the secondary treatments. 9 (12.7%) patients obtained 11
times pregnancy and achieved 10 live births. Therefore,
a total of 30 patients died during the initial treatments
or after recurrence. The overall five-year survival (OS)
rate of all patients was 71.1% (Figure 1A). However, theore or during first cycle of chemotherapy
rum Site of
metastases
Chemotherapy Cause of death




Not done Septic shock
Lung/brain 5-FU*1d Brain herniation
Lung/brain EMA*1 Brain herniation




FAEV*1d Multiple organ failure
Lung/brain FAEV*3d Brain stem hemorrhage
Lung/brain FAEV*4d Brain herniation
uridine, dactinomycin, etoposide, and vincristine; 5-FU: fluorouracil.
Figure 1 Kaplan-Meier curve for (A) overall survival of patients of GTN with brain metastases (n = 101) excluding 8 early-death patients, (B) survival of
patients without versus with previous multidrug chemotherapy failure history, (C) survival of patients with isolated brain metastases versus concurrence
of kidney metastases, (D) survival of patients with FIGO score ≤12 versus > 12.
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our hospital was 85.5%, and this fell to 51.9% in patients
transferred to us from other centres with multidrug
chemotherapy failure history (P < 0.001).
Prognostic variables
Univariate analysis showed that age (P = 0.020), interval
time from antecedent pregnancy (P = 0.018), number of
distant metastatic sites (P = 0.030), multi-agent chemo-
therapy failure history (P < 0.001, Figure 1B), concur-
rence with liver (P = 0.013) or kidney metastases (P =
0.042, Figure 1C), craniotomy (P = 0.029), and FIGO
score (P = 0.018, Figure 1D), were associated with prog-
nostic significance (Table 3).
Multivariate analysis demonstrated that FIGO score
over 12 (Hazard ratio-HR 1.279, 95% CI 1.061-1.541,
P = 0.010), failure of previous multidrug chemotherapy
(HR 3.177, 95% CI 1.277-7.908, P = 0.013), and con-
curret with renal metastasis (HR 2.654, 95% CI 1.125-
6.261, P = 0.026) were independently significant for
poor survival (Table 4). While, the presence of the
liver metastases was not an independent poor prog-
nostic factor (HR 1.681, 95% CI 0.749-3.149, P =
0.208).Discussion
As the first curable solid tumor by chemotherapy, the
cure rate of patients with GTN is more than 90% by the
current chemotherapy regimens [17]. However, there are
still a small proportion of the patients who die from
treatment failure, especially for those with distant metas-
tasis. Brain is the most common distant artery metastatic
site of GTN. In the present study, the patients with brain
metastasis presented a death rate of 29.7%, which was
much higher than the reported 5% overall death rate of
GTN [18]. Therefore, effective management of the pa-
tients with brain metastasis from GTN remains a clinical
challenge.
Due to the rarity of the GTN with about 222 cases
documented in the literature and the much less occur-
rence of the brain metastasis from GTN, most published
data have been obtained from studies with small number
patients [5,7,8,10,19-25]. In this retrospective analysis,
we collected 109 cases of brain metastasis in GTN dur-
ing a 24-year period. To the best of our knowledge, this
study is the largest number of patients to explore the
management, clinical outcomes and relevant risk factors
associated with prognosis of GTN patients with brain
metastasis.
Table 3 Univariate analysis of prognostic factors in patients with brain metastasis of GTN
Clinical Factors Survival rate (%) P value
Age
<40(n = 92) 73.9
≥40(n = 9) 33.3 0.020
Antecedent pregnancy
Abortion(n = 24) 50
Mole(n = 36) 75
Term(n = 41) 78 0.063
Interval time(mos.) from antecedent pregnancy
<13(n = 38) 84.2
≥13(n = 63) 61.9 0.018
No. of metastasis
≤4(n = 86) 70.9
>4(n = 15) 66.7 0.461
Pretreatment serum β-hCG level
<100,000(n = 74) 68.9
≥100,000(n = 27) 74.1 0.576
No. of distant metastatic sitesa
1(n = 71) 78.9
≥2(n = 30) 50 0.030
No. of multi-agent chemotherapy failure history
No(n = 57) 84.2
Yes(n = 44) 52.3 <0.001
Liver metastasis
No(n = 86) 74.4
Yes(n = 15) 46.7 0.013
Kidney metastasis
No(n = 90) 73.3
Yes(n = 11) 45.5 0.042
Pelvic surgeryb
No(n = 75) 74.7
Yes(n = 26) 57.7 0.082
Lung surgeryc
No(n = 68) 67.6
Yes(n = 33) 75.8 0.359
Craniotomy
No(n = 77) 66.2
Yes(n = 24) 83.3 0.029
FIGO score
≤12(n = 38) 84.2
>12(n = 63) 61.9 0.018
a Including brain, liver, kidney, and several unusual sites, e.g. the spinal cord, bladder, adrenal gland, intestinal tract, skin and bone;
b hysterectomy or uterine lesions resection;
c lobectomy or lung lesion resection.
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Table 4 Multivariate analysis of the prognosis of the
patients with brain metastasis from GTN
Variable Hazard ratio 95% CI P value
Age 0.987 0.938-1.039 0.611
Interval time (mos.) from AP 0.564 0.147-2.158 0.403
Multi-agent failure therapy 3.177 1.277-7.908 0.013
Liver metastasis 1.897 0.787-4.573 0.154
Kidney metastasis 2.654 1.125-6.261 0.026
Craniotomy 1.835 0.565-5.962 0.312
FIGO score 1.279 1.061-1.541 0.010
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[6], the outcome of patients with brain metastases from
GTN was improved with multimodal therapy including
craniotomy, whole brain radiotherapy, and EMA-EP or
EMA-CO chemotherapy. Nonetheless, brain metastasis
from GTN is a grave disease with a median survival time
of about 12 months from diagnosis of brain metastasis.
Our results showed that GTN metastastic to brain was
curable if the patients did not have an early death, with
the overall five-year survival rate of 71.1%. The aggres-
sive chemotherapy is the first choice for these patients.
In view of our experience with chemotherapy for GTN,
5-FU (before 2000 years) or FUDR (since 2000 years)-
based combination chemotherapy was favorable in the
management of GTN in our hospital for half of a cen-
tury [13,14,26]. In our center, 5-FU, dactinomycin, vin-
cristine (FAV) is the preferred combined chemotherapy
for patients with high-risk GTN. According to the ac-
cepted guidelines that have a different mechanism of ac-
tion in selecting agents for combination chemotherapy,
etoposide is a useful anticancer agent and has a different
mechanism of action to 5-FU and dactinomycin. More-
over, etoposide is included in available chemotherapy
regimens for high-risk GTN in vast literatures [1,27-29].
Therefore, FAEV combined with intrathecal methotrex-
ate chemotherapy is the first-line chemotherapy for the
patients with brain metastases from GTN in PUMCH.
Furthermore, our earlier report the FAEV is also an ef-
fective regimen with manageable toxicity for patients
with relapsed/chemoresistant GTN[14]. Thus, it is also
used as second-line or third-line treatment for the pa-
tients treated secondarily in our hospital. In this study,
for the 57 patients in the FAEV regimens as the primary
treatment group, 41 patients (71.9%) achieved CR. This
strongly suggested that primary treatment with FAEV
combined with intrathecal methotrexate can produce
good outcomes in brain metastatistic GTN. However,
becase of salvage therapy being more likely to fail in
heavily pre-treated patients [14], in the salvage treatment
group, only 20 patients (45.5%) achieved CR. During the
follow-up time, there were only 9 patients (12.6%)relapsed and 4 of them were still alive at the time of ana-
lysis. 9 patients (12.7%) obtained 11 times pregnancy
and achieved 10 live births. Hence, these data clearly
confirmed that the patients with brain metastasis GTN
could have a good outcome with systematic chemother-
apy plus intrathecal injection of methotrexate.
Time is of the essence in the management of GTN,
and it’s crucial to realize that the patients should receive
early life-saving and standard therapy, preferably in spe-
cialist centers. In the present study, eight patients (7.3%)
with large tumor burden of disease died before or during
first cycle of chemotherapy. This is because of consider-
able delay in the diagnosis and the substandard treat-
ment in the local hospital. Therefore, delay in the
initiation of treatment could adversely affect the progno-
sis, and early life-saving treatment such as craniotomy is
quite necessary for these patients. Among the 101 pa-
tients, there were 24 patients (22.0%) received craniot-
omy, 15 of whom were emergency craniotomy because
of the life-threatening high intracranial pressure second-
ary to hemorrhage and edema. After treatment, 14 pa-
tients (93.3%) achieved CR in the 15 cases. But only 6
patients (66.7%) achieved CR for the remaining 9 pa-
tients who received craniotomy either because of the
brain metastases as the primary clinical manifestations
of GTN or to remove the foci of chemotherapy resistant
disease. Indeed, the univariate analysis showed the prog-
nosis in patients who received craniotomy were signifi-
cantly improved (P = 0.029). This strongly suggested that
the craniotomy play a role in selected patients with brain
metastases from GTN, especially in patients who display
rapidly deteriorating signs, because this operation can
save the patient’s life and help to win time for them to
receive subsequent systemic chemotherapy. In addition,
a failed prior chemotherapy history was the single im-
portant poor prognostic factor for survival, especially for
those who received nonstandard treatment before trans-
ferred to our hospital. The substandard chemotherapy
not only delayed the duration of the disease which
would lead to the widespread of the disease, but also
easily developed to chemoresistant and recurrent dis-
ease. The multivariate analysis demonstrated that previ-
ous multidrug chemotherapy failure history (HR 3.177,
95% CI 1.277-7.908, P = 0.013) was an independent poor
prognostic indicator for survival. Actually, the OS of the
patients treated secondarily in our hospital was 51.9%,
much less than 85.5% of patients who received the pri-
mary treatment in our hospital (univariate analysis, P <
0.001). This result is also supported by the previous
studies [5,13,30]. Therefore, in order to improve the sur-
vival of patient with brain metastasis of GTN, early diag-
nosis and standard treatments should be promptly
applied at specialist centers to prevent the development
of drug resistance and multiorgan metastasis.
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therapy, we seldom use the cranial radiation therapy since
it can induce long-term intellectual impairment in pa-
tients who are cured [10]. Since the effect on tumor vas-
culature from radiotherapy is a late phenomenon, we do
not think that the use of routine cranial radiation to re-
duce the chance of brain hemorrhage is appropriate. In
fact, the cerebral hemorrhage of these patients is often an
early stage event. Some of them even firstly present with
intracranial hemorrhage and high intracranial pressure. In
this time, emergency craniotomy plays a key role in saving
the patient’s life. In fact, our univariate analysis results
showed that craniotomy was an favorable prognostic fac-
tor (P = 0.029). And in the 15 cases with emergency crani-
otomy, 14 patients (93.3%) achieved a CR. These results
demostrate that it is possible to have a good outcome with
chemotherapy and craniotomy in selected cases.
It is recognized that the interval time between ante-
cedent pregnancy and treatment, the presence of liver
metastasis, and treatment with substandard chemo-
therapy were related to the prognosis of GTN patients
with brain metastasis [5,30]. However, four new fea-
tures were found relevant to poor outcome: more than
one distant metastatic site, concurrence with kidney
metastasis, FIGO score over 12, and age more than
40 years (Table 3). Although the number of distant
metastatic sites was only found to be significant in the
univariate analysis (P = 0.030), this result may still be
important because of widespread nature of the disease.
Differently from the reported poor prognosis of pa-
tients with coincidence of liver metastasis in GTN
[29-31], our multivariate analysis showed that concur-
rence with the liver metastases was not an independ-
ent significant predictor of poor outcome. Instead, the
presence of renal metastasis (P = 0.026) was an inde-
pendently significant prognostic indicator (Table 4).
Indeed, the five-year survival in patients with brain
metastasis and kidney metastasis was 45.5%, much
lower than 74.3% in the patients with brain metastasis
only (Figure 1C). FIGO score over 12 (P = 0.010) is an-
other independent poor prognostic indicator, which is
quite similar with other reported metastatic site of
GTN [13,32].
Our previous study suggested that FAEV regimen
was an effective regimen with manageable toxicity for
high-risk GTN patients; and the major restrictive ad-
verse event of FAEV regimen was hematologic toxicity
[12,14]. In the present study, the regimen was toler-
ated well and the toxic effects were similar to that ob-
served in our previous study [12,14] (data not shown).
Other common adverse events to FAEV regimen were
nausea and vomiting, which were easily circumvented
with the use of standard antiemetics and sometimes in
combination with corticosteroids.Conclusions
In conclusion, we have shown that the patients with
brain metastases from GTN were curable with the use
of combined systemic combination agent chemotherapy
plus intrathecal methotrexate with or without additional
surgeries in selected cases. FAEV regimens combined
with intrathecal MTX chemotherapy can produce favor-
able outcomes for GTN patients with brain metastasis
who were treated primarily. The prognosis for patients
with age over 40 years, presence of kidney metastasis,
previous multidrug chemotherapy failure history, multiple-
site distant metastasis, and FIGO scores over 12 was poor.
Further work needs to be done to improve the prognosis.
For women of childbearing age presenting with unexplain-
able lung or brain metastases, a diagnosis of GTN should
be considered and serum hCG measured as part of the ini-
tial work-up. The best outcomes are achieved when such
patients are transferred to major GTN centers for specia-
lised management delivered by experts.
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